What do hip studies tell you about relief?

Why don't knee results answer a hip question?

Much of the research on PRP made from a person's blood studied knees, which bear weight differently and can't predict your hip. Hip studies are the sounder guide when you're choosing hip care. Even then, no study can promise your own result.

Some hip studies compared PRP with hyaluronic acid, a gel used in joint shots, and a few found more relief with PRP, although the combined results still found no clear gap. Another review found similar relief from PRP, cortisone, the gel shot, and saltwater, but none showed worn hip cartilage growing back.

What does the body do after a hip procedure?

Platelets release proteins while the body responds to an injury. PRP gathers extra platelets by spinning your own blood sample. That action gives researchers a reason to study PRP. It doesn't tell you how much relief a hip will get.

Soreness may ease with time, rest, lighter activity, or hope after a procedure. A study compares PRP with another shot to separate those effects. Lab work shows how cells react under set conditions, while animal work adds detail from a joint that isn't a human hip.

What can the research honestly tell you?

Ask whether people walked, slept, or moved more easily after the named procedure. Then ask when the relief wore off and what harm the study found. Those answers can help you weigh a change in quality of life. They still can't tell you exactly how your hip will respond.

Be careful when soreness relief is called a rebuilt joint. A scan must show a cartilage change before anyone can make that claim. Ask whether the people studied had sore hips or sore knees. You need human hip results when the choice concerns your hip.

Sources

1. A four-arm, multicentre, single-blind phase 2/3 randomized trial of 480 knee OA patients (KL II-IV) compared autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction and allogeneic umbilical-cord-tissue mesenchymal stromal cells against a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another, or to the corticosteroid control, and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events occurred.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.. Nature medicine, 2023. DOI: 10.1038/s41591-023-02632-w.

2. A 2026 systematic review and meta-analysis of 28 randomized trials of intra-articular mesenchymal stem cell-based therapies in knee OA found significant improvements in several pain and function measures (delta-VAS MD -1.67; KOOS pain MD 15.37) but NO significant difference in WOMAC, KOOS quality of life or the Lequesne index, and MRI-based WORMS scores were non-significant - indicating no consistent structural benefit. Its own conclusion: these therapies serve a primarily SYMPTOM-modifying rather than STRUCTURE-modifying role, with higher frequencies of local reactions to weigh against the symptomatic benefit.

   Awad G, et al. — Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.. Clinical rheumatology, 2026. DOI: 10.1007/s10067-026-08042-w.

3. A dual systematic review compared the RCT evidence on injectable orthobiologics for knee OA with how news media describe it. Of 14 qualifying RCTs, 8 showed significant pain improvement and 10 function improvement, with frequent heterogeneity and risk of bias. Of 124 news articles: 79.0% highlighted benefits, only 29.8% mentioned drawbacks, 37.1% used the term 'stem cell' without specifying the product, 35.5% mentioned commercial entities with no disclosure, and 66.1% were favourable in tone. The authors conclude this disconnect encourages unrealistic expectations.

   Zhang EJX, et al. — Disparities in Evidence and Media Portrayal of Injectable Orthobiologics for Knee Osteoarthritis: A Systematic Review of Randomized Trials and News Media.. Orthopaedic journal of sports medicine, 2026. DOI: 10.1177/23259671261443876.

4. A meta-analysis of 9 Level-1 trials (671 patients) of adipose stromal vascular fraction and adipose-derived MSC injections for knee OA found SVF superior to saline or hyaluronic acid on pain and function at 3, 6 and 12 months - but INFERIOR to corticosteroid at 3 months, no different at 6, and only comparable or slightly superior at 12. Adipose-derived MSCs beat saline and conservative care but showed no significant difference versus HA. No serious adverse events were attributed to the injections themselves, though complications associated with the LIPOSUCTION step were observed.

   Han JH, et al. — Intra-articular Stromal Vascular Fraction and Mesenchymal Stem Cell Injections Show Variable Efficacy and Higher Potential Complications Compared to Corticosteroid and Hyaluronic Acid in Treatment of Knee Osteoarthritis: A Meta-analysis of Randomized Controlled Trials.. Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association, 2025. DOI: 10.1016/j.arthro.2025.01.050.

5. The strongest recent POSITIVE signal: a meta-analysis of 10 RCTs (818 patients, KL I-III) found intra-articular MSC injection beat hyaluronic acid at 12 months on WOMAC total (MD -10.22), VAS (MD -1.31) and on the MRI Whole-Organ Magnetic Resonance Imaging Score (MD -26.01), all reaching the minimal clinically important difference, with no significant difference in adverse events. Recorded here at full weight: this result and the negative RESTORE and Mautner trials are both in the literature, and an honest page reports both.

   Jin WS, et al. — Mesenchymal Stem Cells Injection Is More Effective Than Hyaluronic Acid Injection in the Treatment of Knee Osteoarthritis With Similar Safety: A Systematic Review and Meta-analysis.. Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association, 2025. DOI: 10.1016/j.arthro.2024.07.027.

6. A network meta-analysis comparing leukocyte-RICH PRP, leukocyte-POOR PRP and hyaluronic acid for knee OA - one of several recent attempts to explain the field's inconsistency by preparation type rather than by whether the therapy works. Formulation heterogeneity is a real confounder in this literature and is why 'PRP' as a single word is close to meaningless.

   Xu B, et al. — Leukocyte-rich versus leukocyte-poor platelet-rich plasma and hyaluronic acid for knee osteoarthritis: a systematic review and network meta-analysis.. Journal of orthopaedic surgery and research, 2026. DOI: 10.1186/s13018-026-06689-4.

7. A systematic review and meta-analysis of adverse events associated with intra-articular PRP injections for knee OA, compared against other injectates. Included so the safety statement on these pages rests on a pooled adverse-event analysis rather than on the absence of reported harm in individual small trials.

   Nakagawa HF, et al. — Assessment of adverse events and safety associated with intra-articular platelet-rich plasma injections compared to other injectates for knee osteoarthritis: A systematic review and meta-analysis.. PM & R : the journal of injury, function, and rehabilitation, 2026. DOI: 10.1002/pmrj.70141.

8. OA-11, a 56-week phase 3 double-blind placebo-controlled trial, randomized 513 knee OA patients (KL 2-3) to a single intra-articular injection of the Wnt-pathway modulator lorecivivint or vehicle placebo. Lorecivivint MISSED its primary endpoint: 12-week pain NRS change was -2.24 with drug versus -2.49 with placebo (p=0.185), no other endpoint showed a discernible treatment effect, and neither group lost meaningful medial joint space over 52 weeks. Even a purpose-built, well-funded disease-modifying candidate has not beaten a placebo injection.

   Yazici Y, et al. — A Phase 3, 56-week, randomised, double-blind, placebo-controlled study (OA-11) utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritis.. Clinical and experimental rheumatology, 2025. DOI: 10.55563/clinexprheumatol/hjt118.

9. The RESTORE trial - a participant-, injector- and assessor-blinded RCT of 288 adults aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence 2-3) - compared three weekly intra-articular PRP injections against saline placebo, with co-primary endpoints of 12-month knee pain and medial tibial cartilage volume on MRI. PRP did not beat placebo on either. It is the single best-designed test of the specific claim that PRP changes joint structure, and it was negative.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.